Recruitment experience in a phase 0 trial of ABT-888, an inhibitor of poly (ADP-ribose) polymerase (PARP), in patients (pts) with advanced malignancies

被引：0
|
作者：
Gutierrez, M.
Kummar, S.
Horneffer, Y.
Juwara, L.
Chen, A.
Melillo, G.
Pickeral, O.
Tomaszewski, J. E.
Murgo, A. J.
Doroshow, J. H.
机构：
[1] NCI, Bethesda, MD 20892 USA
[2] SAIC Frederick Inc, Frederick, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
14111
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
    Kummar, Shivaani
    Kinders, Robert
    Gutierrez, Martin E.
    Rubinstein, Larry
    Parchment, Ralph E.
    Phillips, Lawrence R.
    Ji, Jiuping
    Monks, Anne
    Low, Jennifer A.
    Chen, Alice
    Murgo, Anthony J.
    Collins, Jerry
    Steinberg, Seth M.
    Eliopoulos, Helen
    Giranda, Vincent L.
    Gordon, Gary
    Helman, Lee
    Wiltrout, Robert
    Tomaszewski, Joseph E.
    Doroshow, James H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) : 2705 - 2711
  • [2] Inhibition of poly (ADP-ribose) polymerase (PARP) by ABT-888 in patients with advanced malignancies: Results of a phase 0 trial
    Kummar, S.
    Kinders, R.
    Gutierrez, M.
    Rubinstein, L.
    Parchment, R. E.
    Phillips, L. R.
    Low, J.
    Murgo, A. J.
    Tomaszewski, J. E.
    Doroshow, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Phase 0 pharmacodynamic, pharmacokinetic study of ABT-888, an inhibitor of poly (ADP-ribose) polymerase (PARP), in patients with advanced malignancies
    Kummar, S.
    Gutierrez, M.
    Kinders, R.
    Rubinstein, L.
    Parchment, R. E.
    Phillips, L.
    Ji, J.
    Chen, A.
    Homeffer, Y.
    Juwara, L.
    Yancey, M.
    Murgo, A. J.
    Collins, J. M.
    Tomaszewski, J. E.
    Doroshow, J. H.
    ANNALS OF ONCOLOGY, 2008, 19 : 20 - 20
  • [4] Discovery and SAR of ABT-888, an inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer
    Zhu, Gui-Dong
    Gong, Jianchun
    Gandhi, Viraj B.
    Luo, Yan
    Liu, Xuesong
    Shi, Yan
    Klinghofer, Vered
    Johnson, Eric F.
    Frost, David
    Donawho, Cherrie
    Rodriguez, Luis
    Bukofzer, Gail
    Jarvis, Ken
    Bouska, Jennifer
    Olson, Amanda
    Marsh, Kennan C.
    Park, Chang
    Rosenberg, Saul
    Giranda, Vincent L.
    Penning, Thomas D.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 716 - 716
  • [5] Preliminary results of a phase I trial of ABT-888, a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with cyclophosphamide.
    Tan, A. R.
    Gibbon, D.
    Stein, M. N.
    Moss, R. A.
    Karantza, V.
    Lin, H.
    Gounder, M.
    Chen, A. P.
    Egorin, M. J.
    DiPaola, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies
    Leonard J. Appleman
    Jan H. Beumer
    Yixing Jiang
    Yan Lin
    Fei Ding
    Shannon Puhalla
    Leigh Swartz
    Taofeek K. Owonikoko
    R. Donald Harvey
    Ronald Stoller
    Daniel P. Petro
    Hussein A. Tawbi
    Athanassios Argiris
    Sandra Strychor
    Marie Pouquet
    Brian Kiesel
    Alice P. Chen
    David Gandara
    Chandra P. Belani
    Edward Chu
    Suresh S. Ramalingam
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 1289 - 1301
  • [7] Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies
    Appleman, Leonard J.
    Beumer, Jan H.
    Jiang, Yixing
    Lin, Yan
    Ding, Fei
    Puhalla, Shannon
    Swartz, Leigh
    Owonikoko, Taofeek K.
    Harvey, R. Donald
    Stoller, Ronald
    Petro, Daniel P.
    Tawbi, Hussein A.
    Argiris, Athanassios
    Strychor, Sandra
    Pouquet, Marie
    Kiesel, Brian
    Chen, Alice P.
    Gandara, David
    Belani, Chandra P.
    Chu, Edward
    Ramalingam, Suresh S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (06) : 1289 - 1301
  • [8] ABT-888: A potent and orally efficacious inhibitor of poly(ADP-ribose)polymerase
    Penning, Thomas D.
    Zhu, Gui-Dong
    Gandhi, Viraj B.
    Gong, Jianchun
    Liu, Xuesong
    Shi, Yan
    Klinghofer, Vered
    Johnson, Eric F.
    Donawho, Cherrie K.
    Frost, David J.
    Bontecheva-Diaz, Velkitchka
    Bouska, Jennifer J.
    Osterling, Donald J.
    Olson, Amanda M.
    Marsh, Kerman C.
    Luo, Yan
    Giranda, Vincent L.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 238
  • [9] Liquid Chromatographic Determination of NSC 737664 (ABT-888: An Inhibitor of Poly(ADP-ribose) Polymerase (PARP)) in Plasma and Urine in a Phase 0 Clinical Trial
    Phillips, Lawrence R.
    Hill, Kimberly D.
    Majerova, Eva
    JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES, 2009, 32 (02) : 261 - 272
  • [10] Erlotinib Induces Synthetic Lethality With the Poly(ADP-Ribose) Polymerase (PARP) Inhibitor ABT-888 in Esophageal Cancer
    Whitley, A. C.
    Jackson, J.
    Trummell, H.
    Bonner, J.
    Yang, E. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S165 - S166
12345